You are now leaving Amgen's website www.amgencare.ie and entering another website. Amgen is not responsible for the content of this third-party website you are entering now and is not adopting such content into this website. If you want to leave www.amgencare.ie please click continue:

Return to Previous Page Continue

Neupogen^® (filgrastim) - information for patients

Considerations before starting Neupogen^®

Your doctor will take you through the things you need to consider when preparing to take Neupogen^®. Further information is also available in the Neupogen^® Patient Information Leaflet.

Things to consider when starting on Neupogen^®1

Do not use Neupogen^®:

if you are allergic to filgrastim or any of the other ingredients of this medicine (sodium acetate, sorbitol (E420), polysorbate 80, water for injections).

Please tell your doctor before starting treatment if you have:

Sickle cell anaemia, as Neupogen^® may cause sickle cell crisis.

An allergy to natural rubber (latex). The needle cover on the syringe may be made from a type of natural rubber and may cause allergic reactions.

Osteoporosis (bone disease).

If you are a patient with severe chronic neutropenia, you may be at risk of developing cancer of the blood (leukaemia, myelodysplastic syndrome (MDS)). You should talk to your doctor about your risks of developing cancers of the blood and what testing should be done. If you develop or are likely to develop cancers of the blood, you should not use Neupogen®, unless instructed by your doctor.

Other medicines and Neupogen®

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Take special care with other products that stimulate white blood cells: Neupogen^® is one of a group of products that stimulate the production of white blood cells. Your healthcare professional should always record the exact product you are using.

Pregnancy and breast-feeding

Neupogen^® has not been tested in pregnant or breast-feeding women. Neupogen^® is not recommended during pregnancy.
It is important to tell your doctor if you:

Are pregnant or breast-feeding;
Think you may be pregnant; or
Are planning to have a baby.

If you become pregnant during Neupogen^® treatment, please inform your doctor.
Unless your doctor directs you otherwise, you must stop breast feeding if you use Neupogen^®.

Driving and using machines

Neupogen^® may have a minor influence on your ability to drive and use machines. This medicine may cause dizziness. It is advisable to wait and see how you feel after taking Neupogen^® and before driving or operating machinery.

References:

Neupogen^® (filgrastim). Patient Information Leaflet. [Available at: www.medicines.ie/medicines/list/all/page-1/per-page-25?query=neupogen]

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Side effects can be reported directly to the Health Products Regulatory Authority (HPRA) using the available methods via www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Amgen Limited on +44 (0) 1223 436441 or Freephone 1800 535 160.

Please report any potential quality issue with the Amgen product you have received, by calling us on +44 (0) 1223 436441 or Freephone 1800 535 160 and providing us with the details. Please ensure that you keep your packaging, so we are able to identify your product more easily.

For a list of possible side effects, please see

Patient Information Leaflet (PIL)

Neupogen® (filgrastim) - information for patients Considerations before starting Neupogen®

Things to consider when starting on Neupogen®1

Do not use Neupogen®: